{"filing":{"accession_number":"0001493152-26-038651","cik":"0002029039","ticker":"NSRX","company_name":"Nasus Pharma Ltd","form":"6-K","filing_date":"2026-08-17","report_date":"2026-06-30","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2029039/000149315226038651/form6-k.htm"},"events":[{"id":28144,"run_id":25727,"accession_number":"0001493152-26-038651","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This exhibit is a press release announcing Nasus Pharma's first-half 2026 financial results, including unaudited interim condensed consolidated balance sheets and statements of operations for the six months ended June 30, 2026. The disclosure includes key financial metrics (cash position of $11.9 million, R\u0026D expenses of $2.6 million, net loss of $5.9 million) and clinical program updates. While the exhibit also mentions the appointment of Brendan O'Grady as CEO, the primary substance is the financial results announcement, making this an earnings_release rather than an exec_appointment event.","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":[{"id":29967,"accession_number":"0001493152-26-038651","item_number":"EX-99.3","item_title":"ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Nasus Pharma's first-half 2026 financial results, including unaudited interim condensed consolidated balance sheets and statements of operations for the six months ended June 30, 2026. The disclosure includes key financial metrics (cash position of $11.9 million, R\u0026D expenses of $2.6 million, net loss of $5.9 million) and clinical program updates. While the exhibit also mentions the appointment of Brendan O'Grady as CEO, the primary substance is the financial results announcement, making this an earnings_release rather than an exec_appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:41:44.703697+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29965,"accession_number":"0001493152-26-038651","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim condensed consolidated financial statement for the six-month period ended June 30, 2026. The document explicitly states \"UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026\" and includes balance sheets, statements of operations, changes in shareholders' equity, and cash flows for the interim period. This is a periodic financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:41:44.703697+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-17"},{"id":29966,"accession_number":"0001493152-26-038651","item_number":"EX-99.2","item_title":"ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) of financial condition and results of operations for the six months ended June 30, 2026. It is part of an interim financial report filed on Form 6-K by a foreign private issuer, presenting unaudited interim condensed consolidated financial statements and comparative results. This is a periodic interim financial report, not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:41:44.703697+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-17"},{"id":29967,"accession_number":"0001493152-26-038651","item_number":"EX-99.3","item_title":"ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Nasus Pharma's first-half 2026 financial results, including unaudited interim condensed consolidated balance sheets and statements of operations for the six months ended June 30, 2026. The disclosure includes key financial metrics (cash position of $11.9 million, R\u0026D expenses of $2.6 million, net loss of $5.9 million) and clinical program updates. While the exhibit also mentions the appointment of Brendan O'Grady as CEO, the primary substance is the financial results announcement, making this an earnings_release rather than an exec_appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:41:44.703697+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-17"}]}